In order to sustain oncology care, biosimilars have been proposed as a cost-effective treatment option that may serve to improve affordability and access to therapy [1]. The particular interest in ...
No takes yet. Share an insight, caveat, or question.
Steven Simoens (2020) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: